Common questions about Apriso (FAQ)
Q: How does Apriso compare to other mesalamine medications?
A: Apriso is a brand-name medication whose active ingredient is mesalamine. According to official product information, it is uniquely formulated as an extended-release capsule that is designed for targeted delivery throughout the colon. The formulation supports the once-daily regimen described in the product label. Other mesalamine products may have different release mechanisms and require different dosing schedules.
Q: Does Apriso help with symptoms other than inflammation?
A: Apriso's approved use is for the maintenance of remission of ulcerative colitis, a condition associated with chronic inflammation. The clinical studies used to evaluate its effect measured outcomes related to daily functioning and patterns of physical discomfort. These measured outcomes reflect key symptoms of ulcerative colitis, such as stool frequency and rectal bleeding.
Q: Can Apriso cause stomach upset or nausea?
A: Official safety data indicates that various gastrointestinal effects may occur while taking Apriso. Common side effects reported during clinical trials include abdominal pain, flatulence, and diarrhea. Nausea is also listed as a potential side effect, though it may be reported less commonly (incidence less than 3%) than other gastrointestinal issues.
Q: Are there any long-term side effects associated with Apriso?
A: Severe adverse reactions, such as renal impairment and heart lining inflammation (myocarditis/pericarditis), have been associated with mesalamine products. Official guidance indicates that patient monitoring is necessary during the course of treatment due to the potential for these issues.
Q: What are the signs of a serious allergic reaction to Apriso?
A: Serious hypersensitivity reactions can affect internal organs like the heart, and very rare but severe skin reactions like Stevens-Johnson Syndrome (SJS) have been reported with mesalamine use. Additionally, symptoms that resemble a worsening ulcerative colitis flare—such as fever, acute abdominal pain, or bloody diarrhea—may be signs of a condition called mesalamine-induced acute intolerance syndrome.
Q: Is Apriso the same as generic mesalamine?
A: Apriso is a brand-name drug. While its active ingredient is mesalamine, it is specifically manufactured as an extended-release capsule using technology designed for targeted release in the colon. Generic mesalamine is available, but it comes in various formulations that may have different release patterns and administration instructions.
Q: Is it common to have headaches when first starting Apriso?
A: Official safety data indicates that headache is among the most frequently reported side effects observed in clinical trials, occurring in 3% or more of patients. The product label does not specifically comment on whether this side effect is more common at the beginning of therapy compared to longer-term use.
Q: Why do people sometimes switch from other mesalamine products to Apriso?
A: The main distinction of Apriso is its once-daily regimen and extended-release capsule formulation. These unique features are factors that healthcare providers consider when selecting a long-term treatment plan to help maintain remission of ulcerative colitis.
Q: How long can a person stay on Apriso safely?
A: The medication is indicated for the long-term maintenance of remission. Controlled clinical studies provided data over a six-month period, with some patients followed in an uncontrolled study for up to 24 months. Official guidance specifies that regular monitoring of kidney function and blood cell counts is necessary during treatment.
Q: What is the general success rate mentioned in Apriso research?
A: Clinical studies focused on the drug’s ability to help patients maintain a relapse-free state over a six-month period. Official sources indicate that in two controlled trials, Apriso demonstrated a statistically significant difference compared to an inactive substance (placebo) in the proportion of patients who maintained remission of ulcerative colitis.
Q: Does Apriso contain sulfa?
A: No, Apriso's active ingredient is mesalamine (5-aminosalicylic acid), and it does not contain a sulfa component. However, the regulatory label does state that the medication is contraindicated in patients with a known hypersensitivity to sulfasalazine (a drug that contains a sulfa component and is metabolized into mesalamine).
Q: What does 'maintaining remission' mean in the context of Apriso?
A: Maintaining remission refers to sustaining a period where the symptoms of chronic ulcerative colitis are inactive or quiet. Apriso's therapeutic purpose is to sustain this period of low disease activity, reducing the likelihood of a symptom flare-up.
Q: Does Apriso cause weight gain?
A: Weight gain was not reported as a side effect in the controlled clinical trials for Apriso.
Q: Is hair loss a possible side effect of Apriso?
A: Yes, hair loss (alopecia) has been reported in postmarketing experience with mesalamine products, meaning it was noted after the medication became available to the general public.
Q: What happens if a dose of Apriso is missed?
A: Official patient information describes that a missed dose should be taken as soon as it is remembered, unless it is nearly time for the next scheduled dose. In that case, the dose is typically skipped, and the regular schedule is resumed. Instructions caution against taking extra medicine to compensate for a missed dose.
Q: Can Apriso cause sensitivity to the sun?
A: Official safety information indicates that photosensitivity (an increased sensitivity to sunlight) has been reported with the use of mesalamine. Official instructions include taking precautions when spending time outdoors, such as avoiding excessive sun exposure, wearing protective clothing, and using a broad-spectrum sunscreen.
Q: Does taking Apriso impact fertility?
A: Non-clinical animal studies were conducted to evaluate the effects of mesalamine on the ability to reproduce. These studies did not show any evidence of mesalamine causing impaired fertility in either male or female animals.
Q: Can Apriso be used for Crohn's disease?
A: Apriso is approved by regulatory bodies only for the maintenance of remission of ulcerative colitis (UC) in adults. It is not indicated or approved for use in treating Crohn's disease.
Q: Is fatigue a common side effect of Apriso?
A: Yes, fatigue or asthenia is reported as a common side effect of mesalamine products in some clinical trial and postmarketing data. Common means it has been reported to occur in 1% to 10% of patients.
Q: Are there different strengths or forms of Apriso available?
A: Apriso is available as a single strength: an extended-release capsule. The standard once-daily dose for maintenance of remission involves taking four of these capsules.
Q: Do official documents mention any effects of Apriso on mood?
A: While not listed as a common side effect, postmarketing reports for mesalamine products have included effects related to the central nervous system and mood. These reported effects include nervousness, confusion, and anxiety.
Q: Does Apriso come with a specific patient information guide?
A: Yes, regulatory documents require that the product be dispensed with specific patient counseling information. This guide provides essential details regarding proper administration, warnings, and precautions related to the medication.
Q: Can Apriso be taken if I have a history of heart problems?
A: The regulatory label does not list a history of heart problems as a strict contraindication for use. However, mesalamine has been associated with rare hypersensitivity reactions that can cause inflammation of the heart (myocarditis and pericarditis). The product label indicates that monitoring for signs of hypersensitivity is recommended during treatment.
Q: Does Apriso have any interactions with alcohol consumption?
A: Official regulatory documents do not list a specific direct interaction between Apriso and alcohol. General medical guidance suggests that limiting or avoiding alcohol may be advisable, as alcohol consumption could potentially aggravate the underlying ulcerative colitis condition or some side effects.
